trending Market Intelligence /marketintelligence/en/news-insights/trending/sXG5JXRfHVgJOs4jg7TsTA2 content
Log in to other products

Login to Market Intelligence Platform

 /

Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

UroGen's rare bladder cancer drug accepted for US FDA priority review

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


UroGen's rare bladder cancer drug accepted for US FDA priority review

UroGen Pharma Ltd.'s experimental medicine to treat a rare type of bladder cancer has been accepted for priority review by the U.S. Food and Drug Administration.

The medicine, UGN-101, also known as mitomycin gel, is intended for low-grade upper tract urothelial cancer. The drug candidate will receive a decision on approval from the FDA by April 18, 2020, New York-based UroGen said in its Dec. 19 press release.

During clinical trials, UGN-101 was able to reduce or eliminate patients' cancer for about 13 months.

If approved, UGN-101, which has also received orphan-drug, fast-track and breakthrough-therapy designations, will be the first nonsurgical treatment for low-grade upper tract urothelial cancer, according to UroGen.